Orphagen Pharmaceuticals
Orphagen Pharmaceuticals is a biotech company focused on discovering and developing small molecule ligands that modulate orphan nuclear receptors. They are currently developing OR-812, a novel oral therapeutic for inflammatory bowel disease (IBD), targeting the retinoic acid receptor alpha (RARΞ±). Their work is based on an agnostic approach, exploring proprietary lead molecules with potential in autoimmune disease and oncology.
Funding Round: Grant
Funding Amount: $1.7M
Date: 09-Dec-2024
Investors: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Markets: Biotechnology, Pharmaceuticals, Healthtech, Medical
HQ: San Diego, California, United States
Founded: 2001
Website: https://www.orphagen.com/
LinkedIn: https://www.linkedin.com/company/orphagenpharmaceuticals
Crunchbase: https://www.crunchbase.com/organization/orphagen-pharmaceuticals
Similar Startups
ArrePath
Markets: Biotechnology, Pharmaceuticals,...
HQ: Princeton, New Jersey,...
Leave a Comment
Comments
No comments yet.